Quick Answer
Karyopharm Therapeutics Inc. reported Total Revenue of $146.07 million for fiscal year 2025.
Karyopharm Therapeutics Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $146.07M | +0.6% |
| 2024 | $145.24M | -0.5% |
| 2023 | $146.03M | -7.0% |
| 2022 | $157.07M | -25.1% |
| 2021 | $209.82M | +94.1% |
| 2020 | $108.08M | +164.3% |
| 2019 | $40.89M | +34.8% |
| 2018 | $30.34M | +1790.1% |
| 2017 | $1.60M | +942.2% |
| 2016 | $154.0K | -38.4% |
| 2015 | $250.0K | +9.2% |
| 2014 | $229.0K | -40.8% |
| 2013 | $387.0K | -39.0% |
| 2012 | $634.0K | +317.1% |
| 2011 | $152.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $44.04M | +13.6% | +16.1% |
| June 30, 2025 | $37.93M | -11.4% | +26.4% |
| March 31, 2025 | $30.02M | -9.4% | -22.6% |
| September 30, 2024 | $38.78M | +7.7% | -9.4% |
| June 30, 2024 | $42.79M | +13.9% | +29.2% |
| March 31, 2024 | $33.13M | -14.4% | -8.0% |
| September 30, 2023 | $36.01M | -0.4% | -4.2% |
| June 30, 2023 | $37.58M | -5.3% | -2.9% |
- Karyopharm Therapeutics Inc. showed an increase of +0.6% in Total Revenue compared to the prior fiscal year.
- Over the 2011–2025 period, Karyopharm Therapeutics Inc.’s total revenue has grown by 95996.7% (from $152.0 thousand to $146.07 million).
- The most recent figure is from Karyopharm Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: